Zacks Investment Research on MSN4h
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Following Pfizer's disposal, BlackRock Investment Management (UK) Ltd, a unit of BlackRock, will become Haleon's largest ...
The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...
AllAfrica on MSN3d
GSK Rebrands to Haleon Kenya After SeparationUK drugmaker GlaxoSmithKline Limited (GSK) has rebranded to Haleon Kenya Limited, effective March 14, 2025.The rebrand comes after GSK transferred its consumer health business to Haleon to focus on ...
GSK PLC closed 15.77% below its 52-week high of £18.24, which the company reached on May 16th.
GlaxoSmithKline Limited (GSK) in Kenya has officially changed its legal entity name to Haleon Kenya Limited. Haleon ...
Pharmaceutical company GlaxoSmithKline Limited (GSK) in Kenya has officially changed its legal entity name to Haleon Kenya ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback